A Highly Portable Device for Assessment of Mild Traumatic Brain Injury in Deployed and Far-Forward Settings

The purpose of this study is to develop a highly portable, ruggedized diagnostic tool for concussion, EyeBOX Lens (EBLens), that can be utilized in deployed field and far-forward settings. The EBLens will be based on a concussion diagnostic algorithm from the FDA cleared EyeBOX device, developed by Oculogica, and eye-tracking data collected from a wearable set of eye-tracking glasses, developed by Adhawk Microsystems. Once the EBLens is prototyped, an algorithm for diagnosing concussion will be developed that is specifically appropriate for the EBLens via a case-control clinical study comparing 100 concussed to 100 non-concussed subjects (Phase I). Participants, age 18-35 years, will be recruited from the KACH research team and affiliated providers and clinical sites. Concussed individuals will be assessed within 72 hours of concussion. Demographics, basic medical history, symptom severity, a visio-vestibular exam and the EBLens scan will be collected on both injured cases and uninjured controls at a single time point.

The algorithm and the EBLens will be validated in a subsequent, prospective cohort validation study (Phase II) designed for FDA submission. The correlation of the EBLens output with resolution of symptoms will also be observed in longitudinal follow-up of concussed participants in the validation study. The participant population for this study will be cadets recruited from the USMA and young athletes recruited from affiliated sites during baseline concussion testing. Participants will be assessed at baseline at the start of their academic year or sports season. Those participants who experience a concussive injury will be assessed again at three time points; 1) within 72 hours of injury, 2) weekly until and at the time of initiation of a graded return to activity protocol, and 3) upon clearance for unrestricted RTP/RTD.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Concussion, Brain Brain Concussion Brain Diseases Brain Injuries Brain Injuries, Traumatic Central Nervous System Diseases Craniocerebral Trauma Disease Head Injuries, Closed Mild Traumatic Brain Injury Nervous System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Trauma, Nervous System Wounds and Injuries Wounds, Nonpenetrating

Age range

17 year–35 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Keller Army Hospital

West Point, New York, 10996, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

CONCUSSED:

Inclusion criteria

Provide documented informed consent.
Have presented, at any time post injury, for any complaint related to an injury involving either a direct force to the head or a blow to the body that has the potential to transmit a rapid acceleration/deceleration of the head, with or without loss of consciousness, with or without external signs of head injury.
Be a current cadet/enrolled student age 17-34.
Have the ability to provide a complete ophthalmologic, medical, and neurologic history as well as report current medications.

Exclusion criteria

Have penetrating trauma or known skull fracture or intracranial injury.
Have had a conventional head CT or MRI demonstrating evidence of structural brain injury (subdural, epidural or intraparenchymal hemorrhage, edema/mass effect per attending radiologist read).
Be blind (no light perception), have missing or non-functional eyes.
Be unable to open their eyes.
Have a history of unresolved strabismus, diplopia, amblyopia.
Have a history of unresolved cranial nerve III, IV, or VI palsy.
Have a history of unresolved macular edema, retinal degeneration, extensive cataract, or ocular globe disruption.
Have a history of extensive prior eye surgery or scarring (examples include strabismus surgery, scleral buckle repair of retinal detachment, repair of blow out fractures of the orbit and any procedures that would interfere with extraocular muscle movements; prior cataract surgery or Lasik are not exclusions).
Have a prior history of unresolved ocular-motor dysfunctions.
Be intoxicated.

CONTROLS:

Inclusion criteria

Provide documented informed consent.
Be a current cadet/enrolled student age 17-34.
Have the ability to provide a complete ophthalmologic, medical, and neurologic history as well as report current medications.

Exclusion criteria

Have presented, within the prior six months, for any complaint related to an injury involving either a direct force to the head or a blow to the body that has the potential to transmit a rapid acceleration/deceleration of the head, with or without loss of consciousness, with or without external signs of head injury.
Have penetrating trauma or known skull fracture or intracranial injury.
Have had a conventional head CT or MRI demonstrating evidence of structural brain injury (subdural, epidural or intraparenchymal hemorrhage, edema/mass effect per attending radiologist read).
Be blind (no light perception), have missing or non-functional eyes.
Be unable to open their eyes.
Have a history of unresolved strabismus, diplopia, amblyopia.
Have a history of unresolved cranial nerve III, IV, or VI palsy.
Have a history of unresolved macular edema, retinal degeneration, extensive cataract, or ocular globe disruption.
Have a history of extensive prior eye surgery or scarring (examples include strabismus surgery, scleral buckle repair of retinal detachment, repair of blow out fractures of the orbit and any procedures that would interfere with extraocular muscle movements; prior cataract surgery or Lasik are not exclusions).
Have a prior history of unresolved ocular-motor dysfunctions.
Be intoxicated.

Treatment and study plan

EyeBOX Lens (EBLens)

Device

The investigational device, EBLens, consists of eye-tracking scanners and sensors, developed by AdHawk Microsystems, embedded into a rugged pair of eye-glasses. The subject will wear the EBLens form factor while seated about 40 cm from a small handheld computer screen. The subject will be instructed to watch a video on the screen, while trying not to move their head. The operator will then initiate the EBLens test sequence. During this test a video will be displayed on only a portion of the screen (aperture about 1/9 the size of the screen) for 90 seconds. The video aperture will begin in the upper left corner, and, after 10 seconds, moves in a clockwise direction around the screen for 2 cycles, each taking 40 seconds. During the scan, the following data are collected at a frame rate from 100 to 500 Hz:

Gaze coordinates
Pupil sizes
Accelerometer data
Gyroscopic data
Rotation data
Blink data

Primary outcomes

Diagnostic accuracy of acute clinical diagnosis of concussion using EBLens form factor and algorithm

Time frame: Within 72 hours of injury

The EBLens will have at least 70% sensitivity and specificity for diagnosis of acute concussion

Secondary outcomes

Diagnostic accuracy of recovery determination for return to activity and duty (RTA / RTD) using EBLens form factor and algorithm

Time frame: Through study completion, up to one year

The EBLens will have at least 70% sensitivity and specificity for recovery determination for return to activity and duty (RTA / RTD) without complication.

Sponsors and collaborators

Lead sponsor

Oculogica, Inc.

Industry

Collaborators

Congressionally Directed Medical Research Programs

Registry information

Important dates

Study start: 2023
Primary completion: 2025
Study completion: 2025
First posted: Sep 2, 2022
Registry last updated: Jul 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed